A PHASE 2 STUDY OF IBRUTINIB COMBINATION THERAPY IN TRANSPLANT INELIGIBLE INDIVIDUALS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
- Registry ID
- IND.244
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY
- Start date
- 2025-06-07
- Last update
- 2023-05-11
Conditions
- CENTRAL NERVOUS SYSTEM LYMPHOMA
View on source registry